Literature DB >> 9181282

Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature.

T Kitahara1, K Hiromura, A Maezawa, K Ono, N Narabara, S Yano, T Naruse, K Takenouchi, Y Yasumoto.   

Abstract

A 39-year-old Japanese woman had been receiving propylthiouracil for 5 years for hyperthyroidism when she developed myalgia, scleritis, proteinuria, fever, and inflammation of the nose. Examination of a renal biopsy specimen showed focal segmental necrotizing glomerulonephritis. Indirect immunofluorescent staining showed a highly positive perinuclear pattern of anti-neutrophil cytoplasmic antibody (ANCA) in her serum. Enzyme-linked immunosorbent assay (ELISA) of the ANCA showed positivity for anti-proteinase 3, anti-myeloperoxidase, anti-leukocyte elastase, and anti-lactoferrin, but anti-cathepsin G and anti-lysozyme were negative. Because ELISA showed the titer of anti-leukocyte elastase antibody to be markedly elevated, we challenged this data by performing dot blot analysis. The patient's serum reacted with the native form, but not with denatured leukocyte elastase. Propylthiouracil-induced vasculitis was suspected. Symptoms abated within 2 weeks and all values of ANCA were reduced after the drug was withdrawn. Vasculitis is a rare side-effect of propylthiouracil therapy. Recently it was reported in association with ANCA. We present the findings of this patient and compare them with those described in 19 published cases of propylthiouracil-induced vasculitis associated with ANCA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181282

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  11 in total

1.  ANCA positive propylthiouracil induced pyoderma gangrenosum.

Authors:  K Gungor; S Gonen; G Kisakol; O Dikbas; A Kaya
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

2.  Isotretinoin induced small vessel vasculitis: a life-threatening pulmonary-renal syndrome-a case report.

Authors:  Srinadh Annangi; Sara Pasha
Journal:  Ann Transl Med       Date:  2021-04

3.  A comparison of antineutrophil cytoplasmic antibody prevalence in patients treated and untreated for hyperthyroidism.

Authors:  Turan Calhan; Ebubekir Senateş; Egemen Cebeci; Sayid Shafi Zuhur; Fatma Ozbakır; Uğur Görpe
Journal:  Endocrine       Date:  2010-07-11       Impact factor: 3.633

4.  Cimetidine-induced tubulointerstitial nephritis with both MPO-ANCA and PR3-ANCA.

Authors:  Hideki Ueda; Eiji Ishimura; Takayuki Yunoki; Takao Tsuchida; Naoki Matsumoto; Syuichi Jono; Yasuo Imanishi; Masaaki Inaba; Yoshiki Nishizawa
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

5.  A Case of p-ANCA-Positive Propylthiouracil-Induced Pyoderma Gangrenosum.

Authors:  Jong Won Seo; Hyun Ho Son; Joon Hee Choi; Sook Kyung Lee
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

6.  Cutaneous vasculitis in breast cancer treated with chemotherapy.

Authors:  Maida Wong; Jennifer Grossman; Bevra H Hahn; Antonio La Cava
Journal:  Clin Immunol       Date:  2008-07-21       Impact factor: 3.969

7.  Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.

Authors:  Branka Bonaci-Nikolic; Milos M Nikolic; Sladjana Andrejevic; Svetlana Zoric; Mirjana Bukilica
Journal:  Arthritis Res Ther       Date:  2005-07-13       Impact factor: 5.156

8.  Clinical and laboratory characteristics of drug-induced vasculitic syndromes.

Authors:  Allan Wiik
Journal:  Arthritis Res Ther       Date:  2005-08-24       Impact factor: 5.156

9.  Benzylthiouracil-induced glomerulonephritis.

Authors:  Sihem Trimeche Ajmi; Rim Braham; Sarra Toumi; Molka Chadli Chaieb; Amel Maaroufi; Koussay Ach; Larbi Chaieb
Journal:  Case Rep Med       Date:  2009-07-06

10.  Churg-Strauss Syndrome following PTU Treatment.

Authors:  R A M Quax; A J G Swaak; M G A Baggen
Journal:  Int J Rheumatol       Date:  2009-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.